Connection
Robert MacLaren to Lorazepam
This is a "connection" page, showing publications Robert MacLaren has written about Lorazepam.
|
|
Connection Strength |
|
 |
|
 |
|
1.129 |
|
|
|
-
Mueller SW, Preslaski CR, Kiser TH, Fish DN, Lavelle JC, Malkoski SP, MacLaren R. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med. 2014 May; 42(5):1131-9.
Score: 0.463
-
Horinek EL, Kiser TH, Fish DN, MacLaren R. Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions. Ann Pharmacother. 2009 Dec; 43(12):1964-71.
Score: 0.340
-
MacLaren R, Sullivan PW. Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients. Pharmacotherapy. 2005 Oct; 25(10):1319-28.
Score: 0.255
-
MacLaren R, Forrest LK, Kiser TH. Adjunctive dexmedetomidine therapy in the intensive care unit: a retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters. Pharmacotherapy. 2007 Mar; 27(3):351-9.
Score: 0.070